• Profile
Close

Amniotic membrane-umbilical cord grafts show promise for shunt tube coverage

American Academy of Ophthalmology News Mar 05, 2020

This prospective clinical trial compared the long-term safety and efficacy of amniotic membrane-umbilical cord (AM-UC) and pericardium patch grafts for reducing glaucoma shunt tube exposure.

Study design

A total of 81 eyes were randomized to Baerveldt (n=72) or Ahmed (n=9) valves with either AM-UC (n=41) or pericardium (n=40) patch grafts to cover the tube. Researchers used anterior segment OCT to assess patch graft stability and host-tissue integration, with a focus on tube exposure, graft thinning, and graft-related complications.

Outcomes

Patients were followed an average of 29 months. Sequential anterior-segment OCT showed better host-tissue integration and significantly less graft thinning in the AM-UC group than in the pericardium group. Five eyes (12%) in the AM-UC group and 17 (43%) in the pericardium group experienced early graft thinning within 3 months of surgery (P=0.002). Late thinning occurred in 2 AM-UC eyes and 11 pericardium eyes (P=0.007). Graft translucency and cosmetic appearance were superior in the AM-UC graft group. Overall, infection and graft rejection did not correlate with graft type.

Limitations

The major limitations of this study are the variable follow-up durations and inability to measure the pericardium with anterior segment OCT. The follow-up period ranged from 13 to 40 months and it unclear how long each group was followed. The lack of pericardium thickness measurements limited the comparisons to AM-UC thickness. Without the measurements, it is difficult to see the relevance in using anterior segment OCT to compare the grafts. It would have been useful to have the pre- and postoperative graft thickness measurement. Instead of pericardium, it may be preferable to use a graft material that could be reliably measured with this OCT method. Cost comparisons could provide context.

Clinical significance

Amniotic membrane-umbilical cord grafts have potential benefits based on their high-tensile strength, low immunogenicity and host-tissue integration potential. This randomized, controlled trial, however, has not provided convincing evidence to encourage use of this graft over other comparable options.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay